Summary
Introduction
Cougar Biotechnology is a development stage biopharmaceutical company engaged in acquiring and developing products for the treatment of cancer. The company has built its development portfolio through in-licensing product candidate strategy. It currently has rights to three clinical stage drug candidates.
Scope
Contains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors Includes information on suppliers/ partners, shareholding structure and key employees with biographies
Highlights
The company's research portfolio has CB-7630 (abiraterone acetate), for the potential treatment of advanced prostate cancer patients in Phase I/II clinical trials; CB-3304 (noscapine and related analogs), which is being studied in Phase I/II clinical trials for the treatment of non-Hodgkin's lymphoma and multiple myeloma. The company's CB-1089 (Seocalcitol), an analog of Vitamin D being studied at pre-clinical stage for the potential treatment of hormone refractory prostate cancer. The company has not recorded revenues since its inception in 2003. The company is forecast to generate a profit-sharing revenue of $5 million by 2010, mainly due to the company's anticipated marketing partnership for its product CB-7630.
Reasons to Purchase
Access all the important information and analysis on the company in a single report Understand company's strengths, weaknesses, opportunities and threats along with business strategy and value chain Gain access to company's adjusted five year financial data along with key ratios and market capitalization .
|
